{"id":8147,"date":"2023-08-04T11:18:39","date_gmt":"2023-08-04T11:18:39","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=8147"},"modified":"2023-08-04T11:18:39","modified_gmt":"2023-08-04T11:18:39","slug":"gitr-gitrl-pathway","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/gitr-gitrl-pathway\/","title":{"rendered":"GITR \u2013 GITRL Pathway"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-24.png\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-24-1024x1024.png\" alt=\"\" class=\"wp-image-8148\" width=\"254\" height=\"254\" srcset=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-24-1024x1024.png 1024w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-24-300x300.png 300w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-24-150x150.png 150w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-24-768x768.png 768w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-24-270x270.png 270w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-24-230x230.png 230w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-24.png 1127w\" sizes=\"auto, (max-width: 254px) 100vw, 254px\" \/><\/a><\/figure>\n\n\n\n<p>Glucocorticoid-induced TNFR-related protein (GITR; CD357; TNFRSF18) is an activating receptor on the surface of T cells and other immune cells, binding to its ligand GITRL (TNFSF18). Once exposure to tumour antigen activates a T cell, the number of GITR receptors on its surface increases. On the activated T cell, GITR acts as a co-stimulatory receptor, meaning that it is a receptor whose signalling enhances cell reproduction and the generation of cancer-killing activity. Activation of GITR signalling can also help to enhance immunity through the activation of cytotoxic T cells and inhibition of Treg activity.<\/p>\n\n\n\n<p><strong>LIT:<\/strong>\u00a0\u00a0Modulation of GITR for cancer immunotherapy: D.A. Schaer, et al.; Curr. Opin. Immunol.\u00a0<strong>24,<\/strong>\u00a0217 (2012) | Rationale for anti-GITR cancer immunotherapy: D.A. Knee, et al.; Eur. J. Cancer\u00a0<strong>67,<\/strong>\u00a01 (2016)<\/p>\n\n\n\n<p class=\"clear\"><strong>Biologically Active\u00a0GITR and GITRL Proteins<\/strong>\u00a0<\/p>\n\n\n\n<p>See all Biologically Active\u00a0GITR and GITRL Proteins by AdipoGen Life Sciences\u00a0<a href=\"https:\/\/www.caltagmedsystems.co.uk\/pricing_ordering\/index.php?group_1=All&amp;group_2=89&amp;supplier=39&amp;clonality=All&amp;host=All&amp;species=All&amp;applications=All&amp;regulatory_status=All&amp;searchwords=GITR\">here<\/a>.<\/p>\n\n\n\n<p>See all Biologically Active\u00a0GITR and GITRL Proteins by Chimerigen <a href=\"https:\/\/www.caltagmedsystems.co.uk\/pricing_ordering\/index.php?group_1=All&amp;group_2=89&amp;supplier=48&amp;clonality=All&amp;host=All&amp;species=All&amp;applications=All&amp;regulatory_status=All&amp;searchwords=GITR\">here<\/a>.<\/p>\n\n\n\n<p><strong>VALIDATED\u00a0Antibodies for GITR and GITRL Research<\/strong><\/p>\n\n\n\n<p>See all VALIDATED\u00a0Antibodies for GITR and GITRL Research by AdipoGen Life Sciences <a href=\"https:\/\/www.caltagmedsystems.co.uk\/pricing_ordering\/index.php?group_1=All&amp;group_2=82&amp;supplier=39&amp;clonality=All&amp;host=All&amp;species=All&amp;applications=All&amp;regulatory_status=All&amp;searchwords=GITR\">here<\/a>.<\/p>\n\n\n\n<p>See all VALIDATED\u00a0Antibodies for GITR and GITRL Research by Ancell <a href=\"https:\/\/www.caltagmedsystems.co.uk\/pricing_ordering\/index.php?group_1=All&amp;group_2=82&amp;supplier=46&amp;clonality=All&amp;host=All&amp;species=All&amp;applications=All&amp;regulatory_status=All&amp;searchwords=GITR\">here<\/a>.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-a89b3969 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-text-color has-background wp-element-button\" href=\"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=4883\" style=\"color:#fbc100;background-color:#21318f\"><strong>Back to T Cell Immune Checkpoints for Immuno-Oncology Research<\/strong><\/a><\/div>\n<\/div>\n\n\n\n<p>Originally posted on\u00a0<a href=\"https:\/\/adipogen.com\/gitr-gitrl-pathway\/\">adipogen.com\/gitr-gitrl-pathway\/<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.caltagmedsystems.co.uk\/\">Caltag Medsystems&nbsp;<\/a>is the distributor of&nbsp;<a href=\"https:\/\/www.caltagmedsystems.co.uk\/adipogen\/\">Adipogen<\/a>&nbsp;products in the UK and Ireland. If you have any questions about these products, please&nbsp;<a href=\"https:\/\/www.caltagmedsystems.co.uk\/contact.php\">contact<\/a>&nbsp;<a href=\"https:\/\/www.caltagmedsystems.co.uk\/contact.php\">us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glucocorticoid-induced TNFR-related protein is an activating receptor on the surface of T cells and other immune cells, binding to its ligand GITRL.<\/p>\n","protected":false},"author":13,"featured_media":8151,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,1,637],"tags":[279,185,7,683,685],"class_list":["post-8147","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-general-information","category-t-cells","tag-adipogen","tag-antibodies","tag-cancer","tag-proteins","tag-t-cells-2"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=8147"}],"version-history":[{"count":3,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8147\/revisions"}],"predecessor-version":[{"id":8154,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8147\/revisions\/8154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/8151"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=8147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=8147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=8147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}